ERK1/2 Nuclear Translocation Inhibitors via Importin7 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for proliferative diseases such as cancer are limited in effectively inhibiting the nuclear translocation of ERK1/2, which is crucial for proliferation and is often dysregulated in cancer cells.
Innovation Solution
Development of compounds represented by Formulas I and II, which inhibit the nuclear translocation of ERK1/2 by binding to specific sites on the protein, thereby blocking its interaction with importin7 and subsequent nuclear localization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ERK cascade inhibitors are used, then ERK1/2 nuclear translocation is partially inhibited, but cancer cell viability remains high and resistance develops
Solution Approach 1:
The patent introduces importin7 as an intermediary protein that mediates ERK1/2 nuclear translocation. By targeting importin7 with specific inhibitors (compounds of Formula I and II), the nuclear translocation pathway is blocked at the importin7-ERK interaction step, preventing ERK1/2 from entering the nucleus and activating proliferation genes, thereby achieving more effective cancer cell growth inhibition
Solution Approach 2:
The patent modifies the chemical structure of ERK1/2 inhibitors by introducing specific functional groups (carboxylate, sulfonate, or phosphate moieties) at defined positions in the molecule. These structural parameter changes enhance the compounds' ability to bind to importin7 and block nuclear translocation, resulting in improved cancer cell viability reduction and reduced resistance
2Reliability
If MEK inhibitors are used to block ERK activation, then ERK1/2 nuclear translocation is reduced, but synergy with other inhibitors is limited
Solution Approach 1:
The patent segments the ERK cascade inhibition strategy into two distinct mechanisms: (1) MEK inhibitors that block ERK1/2 activation upstream, and (2) importin7 inhibitors (compounds of Formula I and II) that block nuclear translocation downstream. This segmentation allows the two inhibitor classes to work complementarily, with the importin7 inhibitor providing additional blockade at the nuclear entry step, thereby enhancing overall synergy and efficacy in cancer treatment
Data Source
AI summary
Described herein are compounds having Formula I or Formula II:wherein each dashed line independently represents a saturated or unsaturated bond; R1 and R′1 are aryl or heteroaryl as defined herein; and R2 and R′2 are as defined herein. Further described is a method of inhibiting nuclear translocation of ERK1/2 in a cell, by contacting the cell with a compound having Formula I or Formula II. The compounds may also be for use in treating a disease or disorder associated with nuclear translocation of ERK1/2.